Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT01021332 Completed - Clinical trials for Benign Prostatic Hyperplasia

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms

Neptune II
Start date: April 26, 2010
Phase: Phase 3
Study type: Interventional

Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.

NCT ID: NCT01018511 Completed - Clinical trials for Benign Prostatic Hyperplasia

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms

Neptune
Start date: January 2010
Phase: Phase 3
Study type: Interventional

Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.

NCT ID: NCT01003886 Completed - Clinical trials for Prostatic Hyperplasia

A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

Start date: May 2009
Phase:
Study type: Observational

This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.

NCT ID: NCT01002664 Completed - Clinical trials for Benign Prostatic Hyperplasia

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

MCS_LUTS
Start date: May 2010
Phase: Phase 3
Study type: Interventional

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

NCT ID: NCT01002417 Completed - Clinical trials for Benign Prostatic Hyperplasia

MCS in the Treatment of Lower Urinary Tract Symptoms

MCS_LUTS
Start date: July 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

NCT ID: NCT01002274 Completed - Clinical trials for Benign Prostatic Hyperplasia

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

MCS-2-TWN-c
Start date: August 2010
Phase: Phase 3
Study type: Interventional

This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.

NCT ID: NCT01002222 Completed - Clinical trials for Benign Prostatic Hyperplasia

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

MCS-2-US-c
Start date: January 2011
Phase: Phase 3
Study type: Interventional

This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.

NCT ID: NCT00970632 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)

NCT ID: NCT00969072 Completed - Clinical trials for Benign Prostatic Hyperplasia

Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia

Start date: August 2003
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.

NCT ID: NCT00968656 Completed - Breast Cancer Clinical Trials

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

FISO PET/CT
Start date: January 2009
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to see if Positron Emission Tomography (PET) imaging with a radioactive tracer called 18F-ISO-1 can accurately identify how quickly cancer cells are growing or dividing. A second purpose for this study is to determine, by taking pictures, what tissues and organs of the body take up 18F-ISO-1 naturally and to determine how that uptake changes over time.